alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
vfus_ex10-2.htm


    FORM
OF

    UNSECURED
PROMISSORY NOTE

     

    Date:   February
3, 2004

    Maker:  emicropay,
Inc.

    Maker’s
Mailing Address:  5709 Carrington Court Richardson, TX
75082

    Payee:

    Place for
Payment:

    Principal
Amount:

    Annual
Interest Rate:  Six (6%) percent

    Maturity
Date:  On Demand Annual Interest Rate on Matured, Unpaid

    Amounts:  Six
(6%) Terms of Payment:  Principal on demand, with interest payable on
each succeeding anniversary date of note.

     

    Maker
promises to pay to the order of Payee the principal amount plus interest at the
annual interest rate.  This note is payable at the place for payment
and according to the terms of payment.  All unpaid amounts shall be
due by the maturity date.  After maturity, Maker promises to pay any
unpaid principal balance plus interest at the annual rate on matured, unpaid
amounts.  Maker may prepay this note in any amount at any time before
the maturity date without penalty or premium.  Prepayments will be
applied to last maturing principal, and interest on that prepaid principal will
immediately cease to accrue.  If Maker defaults in the payment of this
note, Payee may declare the unpaid principal balance, earned interest, and any
other amounts owed on the note immediately due.  Maker and each
surety, endorser, and guarantor waive all demand for payment, presentation for
payment, notice of intention to accelerate maturity, notice of acceleration of
maturity, protests, and notice of protest, to the extent permitted by
law.  Maker also promises to pay reasonable attorney’s fees and court
and other costs if this note is placed in the hands of an attorney to collect or
enforce this note.  These expenses will bear interest from the date of
advance at the annual interest rate on matured, unpaid amounts.  Maker
will pay Payee these expenses and interest on demand at the place for
payment.  These expenses and interest will become a part of the debt
evidenced by the note and will be secured by any security for
payment.  Interest on the debt evidenced by this note shall not exceed
the maximum rate or amount of nonusurious interest that may be contracted for,
taken, reserved, charged, or received under law.  Any interest in
excess of that maximum amount will be credited on the principal amount or, if
the principal amount has been paid , refunded.  On any acceleration or
required or permitted prepayment, any such excess interest will be canceled
automatically as of the acceleration or prepayment or, if the excess interest
has already been paid, credited on the principal amount or, if the principal
amount of the debt has been paid, refunded.  This provision overrides
any conflicting provisions in this note and all other instruments concerning the
debt.  Each Maker is responsible for all obligations represented by
this note.  When the context requires, singular nouns and pronouns
include the plural.

     

    emicropay,
Inc.

     

    By:  _______________________________

    Keith
Bottner, Pres.
# Continuation of U.S. Drug Interdiction Assistance to the Government of Colombia

# Memorandum for the Secretary of State [and] the Secretary of Defense

By the authority vested in me as President by the Constitution and the laws of the United States, and pursuant to the authority vested in me by section 1012 of the National Defense Authorization Act for Fiscal Year 1995, as amended (22 U.S.C. 2291-4), I hereby certify, with respect to Colombia, that: (1) interdiction of aircraft reasonably suspected to be primarily engaged in illicit drug trafficking in that country's airspace is necessary, because of the extraordinary threat posed by illicit drug trafficking to the national security of that country; and (2) Colombia has appropriate procedures in place to protect against innocent loss of life in the air and on the ground in connection with such interdiction, which includes effective means to identify and warn an aircraft before the use of force is directed against the aircraft.

                        The Secretary of State is authorized and directed to publish this determination in the                         *Federal Register*                         and to notify the Congress of this determination.                    

[FR Doc. 2021-17551

Billing code 4710-10-P
#### Beneficial Homeowner Service Corporation, Respondent, v Hiram Charles, Appellant, et al., Defendants.

[943 NYS2d 904] —

In an action to foreclose a mortgage, the defendant Hiram *1050Charles appeals, as limited by his brief, from so much of an order of the Supreme Court, Nassau County (Adams, J.), entered September 10, 2010, as denied his motion, inter alia, in effect, to vacate his default in appearing or answering, and pursuant to CPLR 3012 (d) to compel the plaintiff to accept his late answer.

Ordered that the order is affirmed insofar as appealed from, with costs.

The Supreme Court providently exercised its discretion in denying the motion of the defendant Hiram Charles, in effect, to vacate his default in appearing or answering, and pursuant to CPLR 3012 (d) to compel the plaintiff to accept his late answer, since he failed to demonstrate the existence of a potentially meritorious defense to the action *(see Intervest Natl. Bank v Ashburton 70, LLC, 87*AD3d 617 [2011]; *Moriano v Provident N.Y. Bancorp,*71 AD3d 747 [2010]). Balkin, J.P., Leventhal, Hall and Cohen, JJ., concur.
EXHIBIT 10


EXHIBIT 10.50   




Description of Oral Extension-B. LeRea Promissory Note




Summary of Terms of the Orally Agreed upon Extension to following Simple Promissory Note (with corresponding exhibit number of original note) under which Registrant is the Borrower. No periodic payments are required and principal and interest are due on the extended due date.







	Original

	 
	 
	 
	 
	 
	 

	Note

	 
	 
	Original

	Oral

	 
	Annual


	Exhibit

	 
	Loan

	Due

	Extension

	 
	%


	Number

	Lender

	Date

	Date

	Date

	Principal

	Rate


	 
	 
	 
	 
	 
	 
	 

	10.47

	B. LeRea

	01/05/2008

	 04/05/08

	12/31/2008

	$5,000.00

	10%
Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Optical Molecular Imaging, Inc. (the Company) hereby certifies that, to his knowledge:

(i) The Annual Report on Form 10-KSB/A of the Company for the fiscal year ended December 31, 2005 (the Report) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                     |  |     |  |                                      
|-------------------- |  | --- |  | -------------------------------------
|Date: August 1, 2006 |  | By: |  | /s/ David Wohlberg                   
|                     |  |     |  | David Wohlberg                       
|                     |  |     |  | President and Chief Operating Officer
#### Thomas Castaldi et al., Appellants, v Raymond J. Mul*700ter et al., Respondents.

—In an action by the purchasers for specific performance and to recover damages for breach of a contract to sell real property, the plaintiffs appeal from a judgment of the Supreme Court, Suffolk County (Jones, J.), entered March 1, 1985, which, after a nonjury trial, denied the remedy of specific performance and instead awarded the plaintiffs their out-of-pocket expenses and the return of down payment, plus interest, attorney’s fees and damages for willful breach.

Judgment affirmed, without costs or disbursements.

The parties entered into a contract for the purchase of the defendants’ house. The defendants were going to purchase another house, but were unable to do so, and although they attempted to find suitable accommodations for themselves and their eight children, their attempts were unsuccessful. After several adjournments of the closing, the plaintiffs brought an action seeking equitable and legal relief. Trial Term properly exercised its discretion in denying the plaintiffs equitable relief upon finding (1) that the defendants made a good-faith effort to find housing and (2) that awarding specific performance would produce hardship to the defendants and their eight children *(see, Da Silva v Musso,*53 NY2d 543; *Hadcock Motors v Metzger, 92*AD2d 1). Trial Term’s denial of loss-of-bargain damages was proper in the absence of proof of value at the time of the breach *(see, Bailey v Morgan,*95 AD2d 883, *affd*62 NY2d 844; *Commercial Cas. Ins. Co. v Roman,*269 NY 451). Mangano, J. P., Niehoff, Rubin and Kunzeman, JJ., concur.
II

105TH CONGRESS

1ST SESSION S. 1475

To suspend temporarily the duty on certain twisted yarn of viscose rayon.

IN THE SENATE OF THE UNITED STATES

NOVEMBER 8, 1997

Mr. D’AMATO introduced the following bill; which was read twice and referred

to the Committee on Finance

A BILL

To suspend temporarily the duty on certain twisted yarn

of viscose rayon.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. TEMPORARY SUSPENSION OF DUTY.

4 (a) IN GENERAL.—Subchapter II of chapter 99 of

5 the Harmonized Tariff Schedule of the United States is

6 amended by inserting in numerical sequence the following

7 new heading:

‘‘ 9902. . Other yarn, single:

Of viscose rayon,

with a twist exceeding 120 turns/

m (provided for in

subheading

5403.32.00) .......... Free No change No change On or before

12/31/2000 ’’.
2

S 1475 IS

1 (b) EFFECTIVE DATE.—The amendment made by

2 subsection (a) applies with respect to goods entered, or

3 withdrawn from warehouse for consumption, on or after

4 the 15th day after the date of enactment of this Act.

Æ
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 1 of 29 PageID #:17
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 2 of 29 PageID #:18
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 3 of 29 PageID #:19
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 4 of 29 PageID #:20
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 5 of 29 PageID #:21
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 6 of 29 PageID #:22
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 7 of 29 PageID #:23
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 8 of 29 PageID #:24
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 9 of 29 PageID #:25
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 10 of 29 PageID #:26
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 11 of 29 PageID #:27
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 12 of 29 PageID #:28
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 13 of 29 PageID #:29
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 14 of 29 PageID #:30
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 15 of 29 PageID #:31
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 16 of 29 PageID #:32
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 17 of 29 PageID #:33
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 18 of 29 PageID #:34
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 19 of 29 PageID #:35
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 20 of 29 PageID #:36
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 21 of 29 PageID #:37
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 22 of 29 PageID #:38
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 23 of 29 PageID #:39
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 24 of 29 PageID #:40
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 25 of 29 PageID #:41
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 26 of 29 PageID #:42
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 27 of 29 PageID #:43
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 28 of 29 PageID #:44
Case: 1:03-cv-06472 Document #: 2 Filed: 09/12/03 Page 29 of 29 PageID #:45
```

[Congressional Bills 105th Congress]
[From the U.S. Government Publishing Office]
[S. 1511 Referred in House (RFH)]

  1st Session
                                S. 1511

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           November 12, 1997

             Referred to the Committee on National Security

_______________________________________________________________________

                                 AN ACT

 
  To amend section 3165 of the National Defense Authorization Act for 
       Fiscal Year 1998 to clarify the authority in the section.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CLARIFICATION OF AUTHORITY.

    (a) Clarification.--Section 3165 of the National Defense 
Authorization Act for Fiscal Year 1998 is amended--
            (1) in subsection (b)(1), by striking out ``under the 
        jurisdiction'' and all that follows through ``Los Alamos 
        National Laboratory'' and inserting in lieu thereof ``under the 
        jurisdiction or administrative control of the Secretary at or 
        in the vicinity of Los Alamos National Laboratory''; and
            (2) in subsection (e), by striking out ``, the Secretary of 
        the Interior'' and all that follows through the end and 
        inserting in lieu thereof ``but not later than 90 days after 
        the submittal of the report under subsection (d)(1)(C), the 
        County and the Pueblo shall submit to the Secretary an 
        agreement between the County and the Pueblo which allocates 
        between the County and the Pueblo the parcels identified for 
        conveyance or transfer under subsection (b).''.
    (b) Effective Date.--The amendments made by subsection (a) shall 
take effect as if included in the provisions of section 3165 of the 
National Defense Authorization Act for Fiscal Year 1998 to which such 
amendments relate.

            Passed the Senate November 9, 1997.

            Attest:

                                                    GARY SISCO,

                                                             Secretary.
```
II

105TH CONGRESS

1ST SESSION S. 1543

To suspend until December 31, 2002, the duty on Benzenesulfonic acid,

4-chloro-2-[[5-hydroxy-3-methyl-1-(3-sulfophenyl)-1H-pyrazol-4-yl]azo]-5-

methyl-,calcium salt (1:1).

IN THE SENATE OF THE UNITED STATES

NOVEMBER 13, 1997

Mr. CHAFEE introduced the following bill; which was read twice and referred

to the Committee on Finance

A BILL

To suspend until December 31, 2002, the duty on

Benzenesulfonic acid, 4-chloro-2-[[5-hydroxy-3-methyl-1-

(3-sulfophenyl)-1H-pyrazol-4-yl]azo]-5-methyl-,calcium

salt (1:1).

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
2

S 1543 IS

1 SECTION 1. SUSPENSION OF DUTY ON BENZENESULFONIC

2 ACID, 4-CHLORO-2-[[5-HYDROXY-3-METHYL-1-

3 (3-SULFOPHENYL)-1H-PYRAZOL-4-YL]AZO]-5-

4 METHYL-,CALCIUM SALT (1:1).

5 Subchapter II of chapter 99 of the Harmonized Tar6 iff Schedule of the United States is amended by inserting

7 in numerical sequence the following new subheading:

‘‘ 9902.32.XX Benzenesulfonic

acid, 4-chloro-2-

[[5-hydroxy-3-

methyl-1-(3-

sulfophenyl)-1Hpyrazol-4-yl]azo]-5-

methyl-,calcium

salt (1:1) provided

for in subheading

3204.17.60 ............ Free No change No change On or before

12/31/2002 ’’.

8 SEC. 2. EFFECTIVE DATE.

9 The amendment made by section 1 applies with re10 spect to goods entered, or withdrawn from warehouse for

11 consumption, on or after the 15th day after the date of

12 the enactment of this Act.

Æ
Case: 1:02-cv-04766 Document #: 23 Filed: 07/18/03 Page 1 of 5 PageID #:98

Case: 1:02-cv-04766 Document #: 23 Filed: 07/18/03 Page 2 of 5 PageID #:99

Case: 1:02-cv-04766 Document #: 23 Filed: 07/18/03 Page 3 of 5 PageID #:100

Case: 1:02-cv-04766 Document #: 23 Filed: 07/18/03 Page 4 of 5 PageID #:101

Case: 1:02-cv-04766 Document #: 23 Filed: 07/18/03 Page 5 of 5 PageID #:102
#### Bhumi Dogra SINGH, Petitioner, v. Eric H. HOLDER, Jr., Attorney General, Respondent.

No. 08-72391.

United States Court of Appeals, Ninth Circuit.

Submitted July 12, 2011.*

Filed July 20, 2011.

Elisa Bell Ross, Esquire, Law Office of Elisa B. Ross, Phoenix, AZ, for Petitioner.

OIL, Nehal Kamani, Carlton Frederick Sheffield, DOJ-U.S. Department of Justice, Washington, DC, Chief Counsel ICE, Office of the Chief Counsel, Department of Homeland Security San Francisco, CA, for Respondent.

Before: SCHROEDER, ALARCÓN, and LEAVY, Circuit Judges.

*

 The panel unanimously concludes this case is suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Bhumi Dogra Singh, a native and citizen of India, petitions for review of the Board of Immigration Appeals’ order dismissing his appeal from an immigration judge’s (“IJ”) decision denying his application for asylum and withholding of removal. We *172have jurisdiction under 8 U.S.C. § 1252. We review for substantial evidence, *Singh v. Ashcroft,*367 F.3d 1139, 1143 (9th Cir.2004), and we deny the petition for review.

Substantial evidence supports the agency’s adverse credibility determination because it was implausible that Singh attended several political party meetings a week but demonstrated no knowledge of the party leader’s arrest and significant election results during the same period. *See id.*In the absence of credible testimony, Singh’s asylum and withholding of removal claims fail. *See Farah v. Ashcroft,*348 F.3d 1153, 1156 (9th Cir.2003).

PETITION FOR REVIEW DENIED.

**

 This disposition is not appropriate for publication and is not precedent except as provided by 9th Cir. R. 36-3.
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Crop Germplasm Research: College Station, TX
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    CareersSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Plains Area College Station, Texas Southern Plains Agricultural Research Center Crop Germplasm Research People & Locations







Julie C McCollum
                        Crop Germplasm Research

                        




                        
                        Biological Science Lab Technician
                        Phone: (979) 862-4802
                        
                        
                        Fax: (979) 260-9333(Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C.
§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the Company) hereby certifies that, to his knowledge:

(i) The Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2010 (the
Report) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and
results of operations of the Company.

| |  |                      |  |  |  |     |  |        |  |                                      
| |  | -------------------- |  |  |  | --- |  | ------ |  | -------------------------------------
| |  |                      |  |  | 
| |  | Date: March 31, 2011 |  |  |  | By: |  |        |  | /s/ Manish Singh                     
| |  |                      |  |  |  |     |  | Name:  |  | Manish Singh, Ph.D.                  
| |  |                      |  |  |  |     |  | Title: |  | President and Chief Executive Officer
Case: 1:04-cv-04159 Document #: 228-3 Filed: 07/01/08 Page 1 of 3 PageID #:1742
Case: 1:04-cv-04159 Document #: 228-3 Filed: 07/01/08 Page 2 of 3 PageID #:1743
Case: 1:04-cv-04159 Document #: 228-3 Filed: 07/01/08 Page 3 of 3 PageID #:1744
<TABLE> <S> <C>

<ARTICLE>          5
<MULTIPLIER>       1

<S>                                                <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END>                                   DEC-31-1999
<PERIOD-END>                                        DEC-31-1999
<CASH>                                                          1,038
<SECURITIES>                                                        0
<RECEIVABLES>                                                  94,446
<ALLOWANCES>                                                        0
<INVENTORY>                                                         0
<CURRENT-ASSETS>                                               95,484
<PP&E>                                                              0
<DEPRECIATION>                                                      0
<TOTAL-ASSETS>                                                 95,484
<CURRENT-LIABILITIES>                                         174,484
<BONDS>                                                             0
<PREFERRED-MANDATORY>                                               0
<PREFERRED>                                                         0
<COMMON>                                                   18,656,881
<OTHER-SE>                                                          0
<TOTAL-LIABILITY-AND-EQUITY>                                   95,484
<SALES>                                                        10,000
<TOTAL-REVENUES>                                               10,000
<CGS>                                                               0
<TOTAL-COSTS>                                                  74,291
<OTHER-EXPENSES>                                                    0
<LOSS-PROVISION>                                                    0
<INTEREST-EXPENSE>                                              6,305
<INCOME-PRETAX>                                               (64,291)
<INCOME-TAX>                                                        0
<INCOME-CONTINUING>                                           (64,291)
<DISCONTINUED>                                                      0
<EXTRAORDINARY>                                                     0
<CHANGES>                                                           0
<NET-INCOME>                                                  (64,291)
<EPS-BASIC>                                                       0
<EPS-DILUTED>                                                       0




</TABLE>